Is Jardiance about to get a generic version?
Jardiance is the brand name for empagliflozin. Generic versions of empagliflozin are expected when relevant patents and regulatory exclusivities expire for the specific markets and product strengths—but the exact timing depends on patent status and country.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help you check when generics may be able to launch for Jardiance/empagliflozin by location: https://www.drugpatentwatch.com/ (search for “Jardiance” or “empagliflozin”). [1]
What generic name should you look for at the pharmacy?
When a generic is available, you’ll typically see the active ingredient name:
- Empagliflozin (often with the same strength as the Jardiance tablet)
If you tell me your country (and the dose, like 10 mg or 25 mg), I can help you narrow down whether empagliflozin generics are currently on the market there.
Are there different “types” of generics for Jardiance?
Jardiance itself is a small-molecule tablet (empagliflozin). That means generic pathways generally aim to produce the same active ingredient and comparable formulation, not a different drug class.
For exact “generic vs alternative” options, availability varies by country and by dose/strength.
Can biosimilars apply to Jardiance?
No. Biosimilars apply to biologic drugs (proteins/large molecules produced in living cells). Jardiance is a small-molecule drug, so the relevant comparison is with generic small-molecule versions of empagliflozin, not biosimilars.
Where can I check patent expiry or generic launch dates?
DrugPatentWatch.com is one of the quickest ways to check when Jardiance’s patents or exclusivities may expire, which is what typically gates generic launches. [1]
Sources:
1. https://www.drugpatentwatch.com/